APO Research
Talk to an analyst

APO RESEARCH · REPORT

Microbiome Therapeutics

The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).

These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.

An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.

Selected research

Industry Growth & Trends

Global Microbiome Therapeutics Industry Growth and Trends Forecast to 2032

2 January 2026121 pages

Choose your research edition.

Industry ResearchMicrobiome Therapeutics Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Microbiome Therapeutics Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Microbiome Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Microbiome Therapeutics Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Microbiome Therapeutics Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).

These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.

An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.

Read the full market overview

According to APO Research, the global Microbiome Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

Report Scope

This report provides a structured, data-driven view of the global Microbiome Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Microbiome Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Microbiome Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Microbiome Therapeutics.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Microbiome Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Microbiome Therapeutics Market by Company

Seres Therapeutics

Assembly Biosciences

Synthetic Biologics

Interxon

PureTech

Synlogic

Enterome BioScience

4D Pharma

Second Genome

AOBiome

C3 Jian

Rebiotix

MicroBiome Therapeutics LLC

Metabiomics

Ritter Pharmaceuticals

Symberix

OpenBiome

Azitra

Symbiotix Biotherapies

Osel

Metabogen

Microbiome Therapeutics Segment by Type

Upper GIT

Lower GIT

Microbiome Therapeutics Segment by Application

C. difficile Infection (CDI)

Inflammatory Bowel Disease (IBD)

Orphan Drug

Immuno-oncology

Others

Microbiome Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Microbiome Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Microbiome Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Microbiome Therapeutics Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Microbiome Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Microbiome Therapeutics Market Share by Region (2021-2026) Table 4. Global Microbiome Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Microbiome Therapeutics Market Share by Region (2027-2032) Table 6. Global Microbiome Therapeutics Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Microbiome Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Microbiome Therapeutics Market Size Share by Type (2021-2026) Table 9. Global Microbiome Therapeutics Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Microbiome Therapeutics Market Size Share Forecasted by Type (2027-2032) Table 11. North America Microbiome Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Microbiome Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Microbiome Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Microbiome Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Microbiome Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Microbiome Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Microbiome Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Microbiome Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Microbiome Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Microbiome Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Microbiome Therapeutics Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Microbiome Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Microbiome Therapeutics Market Size Share by Application (2021-2026) Table 24. Global Microbiome Therapeutics Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Microbiome Therapeutics Market Size Share Forecasted by Application (2027-2032) Table 26. North America Microbiome Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Microbiome Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Microbiome Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Microbiome Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Microbiome Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Microbiome Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Microbiome Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Microbiome Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Microbiome Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Microbiome Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Microbiome Therapeutics Industry Trends Table 37. Microbiome Therapeutics Industry Drivers Table 38. Microbiome Therapeutics Industry Opportunities and Challenges Table 39. Microbiome Therapeutics Industry Restraints Table 40. Global Microbiome Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Microbiome Therapeutics Revenue Market Share by Company (2021-2026) Table 42. Global Microbiome Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Microbiome Therapeutics Key Company Headquarters & Area Served Table 44. Global Microbiome Therapeutics Company, Product Type & Application Table 45. Global Microbiome Therapeutics Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Microbiome Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Seres Therapeutics Company Information Table 49. Seres Therapeutics Business Overview Table 50. Seres Therapeutics Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Seres Therapeutics Microbiome Therapeutics Product Portfolio Table 52. Seres Therapeutics Recent Development Table 53. Assembly Biosciences Company Information Table 54. Assembly Biosciences Business Overview Table 55. Assembly Biosciences Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Assembly Biosciences Microbiome Therapeutics Product Portfolio Table 57. Assembly Biosciences Recent Development Table 58. Synthetic Biologics Company Information Table 59. Synthetic Biologics Business Overview Table 60. Synthetic Biologics Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Synthetic Biologics Microbiome Therapeutics Product Portfolio Table 62. Synthetic Biologics Recent Development Table 63. Interxon Company Information Table 64. Interxon Business Overview Table 65. Interxon Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Interxon Microbiome Therapeutics Product Portfolio Table 67. Interxon Recent Development Table 68. PureTech Company Information Table 69. PureTech Business Overview Table 70. PureTech Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. PureTech Microbiome Therapeutics Product Portfolio Table 72. PureTech Recent Development Table 73. Synlogic Company Information Table 74. Synlogic Business Overview Table 75. Synlogic Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Synlogic Microbiome Therapeutics Product Portfolio Table 77. Synlogic Recent Development Table 78. Enterome BioScience Company Information Table 79. Enterome BioScience Business Overview Table 80. Enterome BioScience Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Enterome BioScience Microbiome Therapeutics Product Portfolio Table 82. Enterome BioScience Recent Development Table 83. 4D Pharma Company Information Table 84. 4D Pharma Business Overview Table 85. 4D Pharma Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. 4D Pharma Microbiome Therapeutics Product Portfolio Table 87. 4D Pharma Recent Development Table 88. Second Genome Company Information Table 89. Second Genome Business Overview Table 90. Second Genome Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Second Genome Microbiome Therapeutics Product Portfolio Table 92. Second Genome Recent Development Table 93. AOBiome Company Information Table 94. AOBiome Business Overview Table 95. AOBiome Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. AOBiome Microbiome Therapeutics Product Portfolio Table 97. AOBiome Recent Development Table 98. C3 Jian Company Information Table 99. C3 Jian Business Overview Table 100. C3 Jian Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. C3 Jian Microbiome Therapeutics Product Portfolio Table 102. C3 Jian Recent Development Table 103. Rebiotix Company Information Table 104. Rebiotix Business Overview Table 105. Rebiotix Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Rebiotix Microbiome Therapeutics Product Portfolio Table 107. Rebiotix Recent Development Table 108. MicroBiome Therapeutics LLC Company Information Table 109. MicroBiome Therapeutics LLC Business Overview Table 110. MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. MicroBiome Therapeutics LLC Microbiome Therapeutics Product Portfolio Table 112. MicroBiome Therapeutics LLC Recent Development Table 113. Metabiomics Company Information Table 114. Metabiomics Business Overview Table 115. Metabiomics Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Metabiomics Microbiome Therapeutics Product Portfolio Table 117. Metabiomics Recent Development Table 118. Ritter Pharmaceuticals Company Information Table 119. Ritter Pharmaceuticals Business Overview Table 120. Ritter Pharmaceuticals Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio Table 122. Ritter Pharmaceuticals Recent Development Table 123. Symberix Company Information Table 124. Symberix Business Overview Table 125. Symberix Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Symberix Microbiome Therapeutics Product Portfolio Table 127. Symberix Recent Development Table 128. OpenBiome Company Information Table 129. OpenBiome Business Overview Table 130. OpenBiome Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. OpenBiome Microbiome Therapeutics Product Portfolio Table 132. OpenBiome Recent Development Table 133. Azitra Company Information Table 134. Azitra Business Overview Table 135. Azitra Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Azitra Microbiome Therapeutics Product Portfolio Table 137. Azitra Recent Development Table 138. Symbiotix Biotherapies Company Information Table 139. Symbiotix Biotherapies Business Overview Table 140. Symbiotix Biotherapies Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio Table 142. Symbiotix Biotherapies Recent Development Table 143. Osel Company Information Table 144. Osel Business Overview Table 145. Osel Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. Osel Microbiome Therapeutics Product Portfolio Table 147. Osel Recent Development Table 148. Metabogen Company Information Table 149. Metabogen Business Overview Table 150. Metabogen Microbiome Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 151. Metabogen Microbiome Therapeutics Product Portfolio Table 152. Metabogen Recent Development Table 153. North America Microbiome Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. North America Microbiome Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 155. North America Microbiome Therapeutics Market Share by Country (2021-2026) Table 156. North America Microbiome Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. North America Microbiome Therapeutics Market Share Forecast by Country (2027-2032) Table 158. Europe Microbiome Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Europe Microbiome Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 160. Europe Microbiome Therapeutics Market Share by Country (2021-2026) Table 161. Europe Microbiome Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Europe Microbiome Therapeutics Market Share Forecast by Country (2027-2032) Table 163. Asia-Pacific Microbiome Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Asia-Pacific Microbiome Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 165. Asia-Pacific Microbiome Therapeutics Market Share by Country (2021-2026) Table 166. Asia-Pacific Microbiome Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Asia-Pacific Microbiome Therapeutics Market Share Forecast by Country (2027-2032) Table 168. Latin America Microbiome Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Latin America Microbiome Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 170. Latin America Microbiome Therapeutics Market Share by Country (2021-2026) Table 171. Latin America Microbiome Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Latin America Microbiome Therapeutics Market Share Forecast by Country (2027-2032) Table 173. Middle East & Africa Microbiome Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 174. Middle East & Africa Microbiome Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 175. Middle East & Africa Microbiome Therapeutics Market Share by Country (2021-2026) Table 176. Middle East & Africa Microbiome Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 177. Middle East & Africa Microbiome Therapeutics Market Share Forecast by Country (2027-2032) Table 178. Research Programs/Design for This Report Table 179. Authors List of This Report Table 180. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Microbiome Therapeutics Product Image Figure 3. Global Microbiome Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Microbiome Therapeutics Market Size (2021-2032) & (US$ Million) Figure 5. Global Microbiome Therapeutics Market Share by Region: 2025 VS 2032 Figure 6. Global Microbiome Therapeutics Market Share by Region (2021-2032) Figure 7. North America Microbiome Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Microbiome Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Microbiome Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Microbiome Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Microbiome Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Upper GIT Image Figure 13. Global Upper GIT Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Lower GIT Image Figure 15. Global Lower GIT Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Microbiome Therapeutics Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Microbiome Therapeutics Market Share by Type 2025 VS 2032 Figure 18. North America Microbiome Therapeutics Market Size Share by Type (2021-2032) Figure 19. Europe Microbiome Therapeutics Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Microbiome Therapeutics Market Size Share by Type (2021-2032) Figure 21. Latin America Microbiome Therapeutics Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Microbiome Therapeutics Market Size Share by Type (2021-2032) Figure 23. C. difficile Infection (CDI) Image Figure 24. Global C. difficile Infection (CDI) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Inflammatory Bowel Disease (IBD) Image Figure 26. Global Inflammatory Bowel Disease (IBD) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Orphan Drug Image Figure 28. Global Orphan Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Immuno-oncology Image Figure 30. Global Immuno-oncology Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Others Image Figure 32. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Global Microbiome Therapeutics Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Microbiome Therapeutics Market Share by Application 2025 VS 2032 Figure 35. North America Microbiome Therapeutics Market Size Share by Application (2021-2032) Figure 36. Europe Microbiome Therapeutics Market Size Share by Application (2021-2032) Figure 37. Asia-Pacific Microbiome Therapeutics Market Size Share by Application (2021-2032) Figure 38. Latin America Microbiome Therapeutics Market Size Share by Application (2021-2032) Figure 39. Middle East and Africa Microbiome Therapeutics Market Size Share by Application (2021-2032) Figure 40. Global Top 5 and 10 Microbiome Therapeutics Players Market Share by Revenue in 2025 Figure 41. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 42. North America Microbiome Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. North America Microbiome Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. North America Microbiome Therapeutics Market Share by Country (2021-2032) Figure 45. Europe Microbiome Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Microbiome Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Microbiome Therapeutics Market Share by Country (2021-2032) Figure 48. Asia-Pacific Microbiome Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Asia-Pacific Microbiome Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Asia-Pacific Microbiome Therapeutics Market Share by Country (2021-2032) Figure 51. Latin America Microbiome Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Latin America Microbiome Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Microbiome Therapeutics Market Share by Country (2021-2032) Figure 54. Middle East & Africa Microbiome Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Middle East & Africa Microbiome Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 56. Middle East & Africa Microbiome Therapeutics Market Share by Country (2021-2032) Figure 57. Years Considered Figure 58. Research Process Figure 59. Key Executives Interviewed

Scope & coverage.

Types
  • Upper GIT
  • Lower GIT
Applications
  • C. difficile Infection (CDI)
  • Inflammatory Bowel Disease (IBD)
  • Orphan Drug
  • Immuno-oncology
  • Others
Companies covered
  • Seres Therapeutics
  • Assembly Biosciences
  • Synthetic Biologics
  • Interxon
  • PureTech
  • Synlogic
  • Enterome BioScience
  • 4D Pharma
  • Second Genome
  • AOBiome
  • C3 Jian
  • Rebiotix
  • MicroBiome Therapeutics LLC
  • Metabiomics
  • Ritter Pharmaceuticals
  • Symberix
  • OpenBiome
  • Azitra
  • Symbiotix Biotherapies
  • Osel
  • Metabogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Microbiome Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Microbiome Therapeutics Market Size by Region (2021-2032)
  5. 1.4.1 Global Microbiome Therapeutics Market Size by Region (2021-2026)
  6. 1.4.2 Global Microbiome Therapeutics Market Size by Region (2027-2032)
  7. 1.5 Key Regions Microbiome Therapeutics Market Size (2021-2032)
  8. 1.5.1 North America Microbiome Therapeutics Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Microbiome Therapeutics Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Microbiome Therapeutics Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Microbiome Therapeutics Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Microbiome Therapeutics Market Size Growth Rate (2021-2032)
2 Microbiome Therapeutics Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Upper GIT
  3. 2.1.2 Lower GIT
  4. 2.2 Global Microbiome Therapeutics Market Size by Type
  5. 2.2.1 Global Microbiome Therapeutics Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Microbiome Therapeutics Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Microbiome Therapeutics Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Microbiome Therapeutics Market Size by Regions
  9. 2.3.1 North America Microbiome Therapeutics Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Microbiome Therapeutics Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Microbiome Therapeutics Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Microbiome Therapeutics Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Microbiome Therapeutics Market Size Breakdown by Type (2021-2026)
3 Microbiome Therapeutics Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 C. difficile Infection (CDI)
  3. 3.1.2 Inflammatory Bowel Disease (IBD)
  4. 3.1.3 Orphan Drug
  5. 3.1.4 Immuno-oncology
  6. 3.1.5 Others
  7. 3.2 Global Microbiome Therapeutics Market Size by Application
  8. 3.2.1 Global Microbiome Therapeutics Market Size Overview by Application (2021-2032)
  9. 3.2.2 Global Microbiome Therapeutics Historic Market Size Review by Application (2021-2026)
  10. 3.2.3 Global Microbiome Therapeutics Market Size Forecasted by Application (2027-2032)
  11. 3.3 Global Microbiome Therapeutics Market Size by Regions
  12. 3.3.1 North America Microbiome Therapeutics Market Size Breakdown by Application (2021-2026)
  13. 3.3.2 Europe Microbiome Therapeutics Market Size Breakdown by Application (2021-2026)
  14. 3.3.3 Asia-Pacific Microbiome Therapeutics Market Size Breakdown by Application (2021-2026)
  15. 3.3.4 South America Microbiome Therapeutics Market Size Breakdown by Application (2021-2026)
  16. 3.3.5 Middle East and Africa Microbiome Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Microbiome Therapeutics Industry Trends
  2. 4.2 Microbiome Therapeutics Industry Drivers
  3. 4.3 Microbiome Therapeutics Industry Opportunities and Challenges
  4. 4.4 Microbiome Therapeutics Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Microbiome Therapeutics Revenue (2021-2026)
  2. 5.2 Global Microbiome Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Microbiome Therapeutics Key Company Headquarters & Area Served
  4. 5.4 Global Microbiome Therapeutics Company, Product Type & Application
  5. 5.5 Global Microbiome Therapeutics Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Microbiome Therapeutics Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Microbiome Therapeutics Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Microbiome Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Seres Therapeutics
  2. 6.1.1 Seres Therapeutics Company Information
  3. 6.1.2 Seres Therapeutics Business Overview
  4. 6.1.3 Seres Therapeutics Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Seres Therapeutics Microbiome Therapeutics Product Portfolio
  6. 6.1.5 Seres Therapeutics Recent Developments
  7. 6.2 Assembly Biosciences
  8. 6.2.1 Assembly Biosciences Company Information
  9. 6.2.2 Assembly Biosciences Business Overview
  10. 6.2.3 Assembly Biosciences Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Assembly Biosciences Microbiome Therapeutics Product Portfolio
  12. 6.2.5 Assembly Biosciences Recent Developments
  13. 6.3 Synthetic Biologics
  14. 6.3.1 Synthetic Biologics Company Information
  15. 6.3.2 Synthetic Biologics Business Overview
  16. 6.3.3 Synthetic Biologics Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Synthetic Biologics Microbiome Therapeutics Product Portfolio
  18. 6.3.5 Synthetic Biologics Recent Developments
  19. 6.4 Interxon
  20. 6.4.1 Interxon Company Information
  21. 6.4.2 Interxon Business Overview
  22. 6.4.3 Interxon Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Interxon Microbiome Therapeutics Product Portfolio
  24. 6.4.5 Interxon Recent Developments
  25. 6.5 PureTech
  26. 6.5.1 PureTech Company Information
  27. 6.5.2 PureTech Business Overview
  28. 6.5.3 PureTech Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 PureTech Microbiome Therapeutics Product Portfolio
  30. 6.5.5 PureTech Recent Developments
  31. 6.6 Synlogic
  32. 6.6.1 Synlogic Company Information
  33. 6.6.2 Synlogic Business Overview
  34. 6.6.3 Synlogic Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Synlogic Microbiome Therapeutics Product Portfolio
  36. 6.6.5 Synlogic Recent Developments
  37. 6.7 Enterome BioScience
  38. 6.7.1 Enterome BioScience Company Information
  39. 6.7.2 Enterome BioScience Business Overview
  40. 6.7.3 Enterome BioScience Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Enterome BioScience Microbiome Therapeutics Product Portfolio
  42. 6.7.5 Enterome BioScience Recent Developments
  43. 6.8 4D Pharma
  44. 6.8.1 4D Pharma Company Information
  45. 6.8.2 4D Pharma Business Overview
  46. 6.8.3 4D Pharma Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 4D Pharma Microbiome Therapeutics Product Portfolio
  48. 6.8.5 4D Pharma Recent Developments
  49. 6.9 Second Genome
  50. 6.9.1 Second Genome Company Information
  51. 6.9.2 Second Genome Business Overview
  52. 6.9.3 Second Genome Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Second Genome Microbiome Therapeutics Product Portfolio
  54. 6.9.5 Second Genome Recent Developments
  55. 6.10 AOBiome
  56. 6.10.1 AOBiome Company Information
  57. 6.10.2 AOBiome Business Overview
  58. 6.10.3 AOBiome Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 AOBiome Microbiome Therapeutics Product Portfolio
  60. 6.10.5 AOBiome Recent Developments
  61. 6.11 C3 Jian
  62. 6.11.1 C3 Jian Company Information
  63. 6.11.2 C3 Jian Business Overview
  64. 6.11.3 C3 Jian Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 C3 Jian Microbiome Therapeutics Product Portfolio
  66. 6.11.5 C3 Jian Recent Developments
  67. 6.12 Rebiotix
  68. 6.12.1 Rebiotix Company Information
  69. 6.12.2 Rebiotix Business Overview
  70. 6.12.3 Rebiotix Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Rebiotix Microbiome Therapeutics Product Portfolio
  72. 6.12.5 Rebiotix Recent Developments
  73. 6.13 MicroBiome Therapeutics LLC
  74. 6.13.1 MicroBiome Therapeutics LLC Company Information
  75. 6.13.2 MicroBiome Therapeutics LLC Business Overview
  76. 6.13.3 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 MicroBiome Therapeutics LLC Microbiome Therapeutics Product Portfolio
  78. 6.13.5 MicroBiome Therapeutics LLC Recent Developments
  79. 6.14 Metabiomics
  80. 6.14.1 Metabiomics Company Information
  81. 6.14.2 Metabiomics Business Overview
  82. 6.14.3 Metabiomics Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Metabiomics Microbiome Therapeutics Product Portfolio
  84. 6.14.5 Metabiomics Recent Developments
  85. 6.15 Ritter Pharmaceuticals
  86. 6.15.1 Ritter Pharmaceuticals Company Information
  87. 6.15.2 Ritter Pharmaceuticals Business Overview
  88. 6.15.3 Ritter Pharmaceuticals Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio
  90. 6.15.5 Ritter Pharmaceuticals Recent Developments
  91. 6.16 Symberix
  92. 6.16.1 Symberix Company Information
  93. 6.16.2 Symberix Business Overview
  94. 6.16.3 Symberix Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Symberix Microbiome Therapeutics Product Portfolio
  96. 6.16.5 Symberix Recent Developments
  97. 6.17 OpenBiome
  98. 6.17.1 OpenBiome Company Information
  99. 6.17.2 OpenBiome Business Overview
  100. 6.17.3 OpenBiome Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 OpenBiome Microbiome Therapeutics Product Portfolio
  102. 6.17.5 OpenBiome Recent Developments
  103. 6.18 Azitra
  104. 6.18.1 Azitra Company Information
  105. 6.18.2 Azitra Business Overview
  106. 6.18.3 Azitra Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Azitra Microbiome Therapeutics Product Portfolio
  108. 6.18.5 Azitra Recent Developments
  109. 6.19 Symbiotix Biotherapies
  110. 6.19.1 Symbiotix Biotherapies Company Information
  111. 6.19.2 Symbiotix Biotherapies Business Overview
  112. 6.19.3 Symbiotix Biotherapies Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio
  114. 6.19.5 Symbiotix Biotherapies Recent Developments
  115. 6.20 Osel
  116. 6.20.1 Osel Company Information
  117. 6.20.2 Osel Business Overview
  118. 6.20.3 Osel Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 Osel Microbiome Therapeutics Product Portfolio
  120. 6.20.5 Osel Recent Developments
  121. 6.21 Metabogen
  122. 6.21.1 Metabogen Company Information
  123. 6.21.2 Metabogen Business Overview
  124. 6.21.3 Metabogen Microbiome Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  125. 6.21.4 Metabogen Microbiome Therapeutics Product Portfolio
  126. 6.21.5 Metabogen Recent Developments
7 North America
  1. 7.1 North America Microbiome Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Microbiome Therapeutics Market Size by Country (2021-2026)
  3. 7.3 North America Microbiome Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Microbiome Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Microbiome Therapeutics Market Size by Country (2021-2026)
  3. 8.3 Europe Microbiome Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Microbiome Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Microbiome Therapeutics Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Microbiome Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Microbiome Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Microbiome Therapeutics Market Size by Country (2021-2026)
  3. 10.3 South America Microbiome Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Microbiome Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Microbiome Therapeutics Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Microbiome Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst